These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3018 related articles for article (PubMed ID: 7646901)
1. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Lejeune FJ Eur J Cancer; 1995 Jun; 31A(6):1009-16. PubMed ID: 7646901 [No Abstract] [Full Text] [Related]
2. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926 [TBL] [Abstract][Full Text] [Related]
3. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. Liénard D; Lejeune FJ; Ewalenko P World J Surg; 1992; 16(2):234-40. PubMed ID: 1561804 [TBL] [Abstract][Full Text] [Related]
4. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Eggimann P; Chioléro R; Chassot PG; Lienard D; Gerain J; Lejeune F Chest; 1995 Apr; 107(4):1074-82. PubMed ID: 7705119 [TBL] [Abstract][Full Text] [Related]
5. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P J Infus Chemother; 1995; 5(2):73-81. PubMed ID: 8521239 [TBL] [Abstract][Full Text] [Related]
6. [Value of isolation-perfusion of the limbs in melanomas and sarcomas]. Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B Ann Chir; 1995; 49(1):9-12. PubMed ID: 7741477 [No Abstract] [Full Text] [Related]
9. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P J Cell Biochem; 1994 Sep; 56(1):52-61. PubMed ID: 7806592 [TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. Fraker DL; Alexander HR; Andrich M; Rosenberg SA J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761 [TBL] [Abstract][Full Text] [Related]
11. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490 [TBL] [Abstract][Full Text] [Related]
12. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Sorkin P; Abu-Abid S; Lev D; Gutman M; Aderka D; Halpern P; Setton A; Kudlik N; Bar-On J; Rudich V Arch Surg; 1995 Oct; 130(10):1079-84. PubMed ID: 7575120 [TBL] [Abstract][Full Text] [Related]
13. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Feelders RA; Vreugdenhil G; Eggermont AM; Kuiper-Kramer PA; van Eijk HG; Swaak AJ Eur J Clin Invest; 1998 Jul; 28(7):520-7. PubMed ID: 9726030 [TBL] [Abstract][Full Text] [Related]
14. Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs. Barker WC; Andrich MP; Alexander HR; Fraker DL Eur J Nucl Med; 1995 Nov; 22(11):1242-8. PubMed ID: 8575471 [TBL] [Abstract][Full Text] [Related]
15. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system. Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416 [TBL] [Abstract][Full Text] [Related]
16. Isolation perfusion with tumor necrosis factor-alpha, interferon-gamma, and hyperthermia in the treatment of localized and metastatic cancer. Yang JC; Fraker DL; Thom AK; Pass HI; Rosenberg SA Recent Results Cancer Res; 1995; 138():161-6. PubMed ID: 7899692 [No Abstract] [Full Text] [Related]
17. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Fraker DL; Alexander HR; Andrich M; Rosenberg SA Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465 [TBL] [Abstract][Full Text] [Related]
18. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors. Schienk S; Liénard D; Gerain J; Baumgartner M; Lejeune FJ; Chiquet-Ehrismann R; Rüegg C Int J Cancer; 1995 Nov; 63(5):665-72. PubMed ID: 7591283 [TBL] [Abstract][Full Text] [Related]
19. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion. Coit DG Cancer J Sci Am; 1995; 1(2):104-5. PubMed ID: 9166460 [No Abstract] [Full Text] [Related]
20. Clinical applications of TNF-alpha in cancer. Lejeune FJ; Rüegg C; Liénard D Curr Opin Immunol; 1998 Oct; 10(5):573-80. PubMed ID: 9794839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]